According to a study published in The Lancet journal, a booster dose of six Covid-19 vaccines is safe and increases strong immune response, it said. It was found that the booster vaccine is a safe and significant immune response in persons who have previously received a two-dose course of AstraZeneca or Pfizer vaccinations.
The six vaccines whose booster doses include AstraZeneca, Pfizer-BioNTech, Novavax, Janssen, Moderna, Valneva, and Curevac. In trials, each of the vaccines- Pfizer and AstraZeneca were studied and it was found to be 79% and 90% protection against hospitalization and mortality after six months.
The latest study examined the safety, immune response, and side effects of seven vaccines when used as a third booster jab. The study conducted by a group of researchers is now being examined for further development to combat the new variant ‘Omicron’.
Boosters have already been given in many countries as the protection against Covid-19 infection decreases over time.
Professor Saul Faust, a trial lead from the University Hospital Southampton NHS Foundation Trust, UK said, “the side effect data show all seven vaccines are safe to use as 3rd doses, with acceptable levels of inflammatory side effects like injection site pain, muscle soreness, fatigue.”
The researchers also said that their findings apply to these vaccines only as boosters for the first two doses. The immune response people get will take at least 28 days they said. A randomized, Phase 2 trial of seven booster vaccines was performed, and the third dose was given 10–12 weeks after the initial two-dose course of AstraZeneca or Pfizer-BioNTech.
The trial involved 2,878 participants in good health recruited at 18 UK sites between June 1 and June 30, 2021. They have experimented with booster doses and half of the participants received two doses of AstraZeneca and half two doses of Pfizer.
Due to the pandemic schedules and the need to provide data to guide the policies for September 2021, the duration taken between the second and third doses in particular individuals is shorter than the period between the two doses.